Copyright
©The Author(s) 2016.
World J Clin Cases. Oct 16, 2016; 4(10): 310-317
Published online Oct 16, 2016. doi: 10.12998/wjcc.v4.i10.310
Published online Oct 16, 2016. doi: 10.12998/wjcc.v4.i10.310
Table 4 Responsible chemotherapeutic agents and response rates to Kampo treatment
| Major response (%) | Minor response (%) | No response (%) | Total(%) | |
| Taxanes | 5 (38.5) | 6 (46.1) | 2 (15.4) | 13 (100.0) |
| Platinum analogues | ||||
| Oxaliplatin | 0 | 2 (100.0) | 0 | 2 (100.0) |
| Cisplatin | 2 (66.7) | 1 (33.3) | 0 | 3 (100.0) |
| Taxanes + cisplatin | 2 (100.0) | 0 | 0 | 2 (100.0) |
| Bortezomib | 0 | 1 (100.0) | 0 | 1 (100.0) |
| Vinca alkaloids | 0 | 0 | 1 (100.0) | 1 (100.0) |
| Bortezomib + vinca alkaloids | 0 | 1 (50.0) | 1 (50.0) | 2 (100.0) |
- Citation: Kimata Y, Ogawa K, Okamoto H, Chino A, Namiki T. Efficacy of Japanese traditional (Kampo) medicine for treating chemotherapy-induced peripheral neuropathy: A retrospective case series study. World J Clin Cases 2016; 4(10): 310-317
- URL: https://www.wjgnet.com/2307-8960/full/v4/i10/310.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v4.i10.310